Audio and slides for this presentation are also available on YouTube: http://youtu.be/ukXhuy5cXrE
Huma Q. Rana, MD, a cancer geneticist with Dana-Farber Cancer Institute, explains the cancer risk associated with BRCA1 and BRCA2 gene mutations. This presentation was originally given on July 23, 2013 as part of the "What Every Woman Should Know" event put on by Dana-Farber's Susan F. Smith Center for Women's Cancers.
BRCA – Importance in Hereditary Breast & Ovarian CancerLifecare Centre
BRCA – Importance in Hereditary
Breast & Ovarian Cancer
DGF & WOW India
presentation was made by
Dr Sharda Jain
based on presentation made by
Dr Sunil Tadepalli
Audio and slides for this presentation are also available on YouTube: http://youtu.be/ukXhuy5cXrE
Huma Q. Rana, MD, a cancer geneticist with Dana-Farber Cancer Institute, explains the cancer risk associated with BRCA1 and BRCA2 gene mutations. This presentation was originally given on July 23, 2013 as part of the "What Every Woman Should Know" event put on by Dana-Farber's Susan F. Smith Center for Women's Cancers.
BRCA – Importance in Hereditary Breast & Ovarian CancerLifecare Centre
BRCA – Importance in Hereditary
Breast & Ovarian Cancer
DGF & WOW India
presentation was made by
Dr Sharda Jain
based on presentation made by
Dr Sunil Tadepalli
Audio and slides for this presentation are available on YouTube: http://youtu.be/ozNSEND5PbE
Erica Mayer, MD, MPH, of the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, discusses triple-negative breast cancer and what makes it different from other forms of breast cancer. Mayer also talks about treatment options for triple-negative breast cancer and what you need to know about clinical trials for the disease.
Audio and slides for this presentation are available on YouTube: http://youtu.be/ozNSEND5PbE
Erica Mayer, MD, MPH, of the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, discusses triple-negative breast cancer and what makes it different from other forms of breast cancer. Mayer also talks about treatment options for triple-negative breast cancer and what you need to know about clinical trials for the disease.
Proteogenomic analysis of human colon cancer reveals new therapeutic opportun...Gul Muneer
We performed the first proteogenomic study on a prospectively collected colon cancer cohort. Comparative proteomic and phosphoproteomic analysis of paired tumor and normal adjacent tissues produced a catalog of colon cancer-associated proteins and phosphosites, including known and putative new biomarkers, drug targets, and cancer/testis antigens. Proteogenomic integration not only prioritized genomically inferred targets, such as copy-number drivers and mutation-derived neoantigens, but also yielded novel findings. Phosphoproteomics data associated Rb phosphorylation with increased proliferation and decreased apoptosis in colon cancer, which explains why this classical tumor suppressor is amplified in colon tumors and suggests a rationale for targeting Rb phosphorylation in colon cancer. Proteomics identified an association between decreased CD8 T cell infiltration and increased glycolysis in microsatellite instability-high (MSI-H) tumors, suggesting glycolysis as a potential target to overcome the resistance of MSI-H tumors to immune checkpoint blockade. Proteogenomics presents new avenues for biological discoveries and therapeutic development.
NSA Diagnostic Laboratory has been operating since 1958, founded by Prof. Nasseh Amin. NSA is considered as one of the most advanced labs in Egypt. Maintaining personalized services for its stakeholders, as well as the main role of the lab "Diagnosis"
NSA Diagnostic Laboratory operates through two different segments.
Firstly, a group of stand-alone labs located at prime locations all over Egypt, with the latest and up to date equipments.
Secondly, being the backbone of well reputed hospitals and some polyclinics where NSA is the lab that is responsible for all medical testing there, serving all our patients with class A quality.
Our main focus is delivering quality care and with Cost-value return. NSA plays a key role in improving the health of many Egyptians, by providing access to quality service for more than 200,000 patients annually.
NSCLC: diagnóstico molecular, pronóstico y seguimiento; CTCMauricio Lema
Lo nuevo en diagnóstico molecular, pronóstico y seguimiento en NSCLC, y el impacto pronóstico de las Células Tumorales Circulantes. Para evento de cirugía de tórax, Hotel Intercontinental, Medellín, 22.05.2018 (se complementa con las la presentación de lo nuevo en terapia sistémica en NSCLC).
FACTORS AFFECTING INITIAL CYCLOSPORINE A LEVEL AND ITS CORRELATION WITH CLINI...Alok Gupta
FACTORS AFFECTING INITIAL CYCLOSPORINE A LEVEL AND ITS CORRELATION WITH CLINICAL OUTCOME INACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
Hepatitis B infection in Stem cell transplant patients and role of lamivudine...Alok Gupta
The presentation describes Hepatitis B infection in Stem cell transplant patients and role of lamivudine prophylaxis in prevention.
The presentation was made at annual meeting of Mumbai Hematology Group held at ACTREC, Mumbai in 2014.
The presentation describes various facts about breast and cervical cancer including burden of disease, survival outcomes, need for early diagnosis and screening recommendations.
Cancer screening - Evidence, Expected benefits, Methods and Current Recommend...Alok Gupta
The presentation discusses about Cancer screening - Evidence, Expected benefits, Methods and Current Recommendations.
The was presented in HEALTH CONNECT meeting at Max Hospital, Saket, new Delhi in 2016.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
Genetics in prostate cancer
1. Molecular and Genetic Understanding of CRPC
Updates from Lab and Lessons for Clinic
Dr Alok Gupta
MD, DM,
Consultant Medical Oncologist
Max Super Speciality Hospital, New Delhi
Ex-Asst. Professor, AIIMS, New Delhi
2. Outline
Genomic alterations in prostate cancer
DNA damage response pathways
DNA repair defects in advanced prostate cancer
Therapeutic implications of DNA repair defects in advanced prostate
cancer
HRD - PARP inhibitors and synthetic lethality
MMR defects and immune checkpoint inhibitors
Conclusions
3. Heritability of prostate cancer (PCa)
Family history is strong risk factor
• Nordic twin study1
• 57% heritability for PCa
• Only melanoma had higher heritability (58%)
• BUT…..identifying specific genes that contribute to this risk has proven challenging
• Genetic linkage studies in multi-case PCa families over 2 decades revealed few
candidates e.g. HOXB13 G84E mutation present in 3.1% of familial PCa2
1Mucci et al. JAMA. 2016 Jan 5;315(1):68-76
2Ewing et al. JAMA. 2016 Jan 5;315(1):68-76
4. Germline DNA repair gene mutations & Prostate Cancer
Higher risk of developing PCa
Mutated gene Increased risk of PCa Reference
BRCA2 Up to 8.6 fold Br J Cancer. 2011;105(8):1230-4
BRCA1 3.75 fold Br J Cancer. 2012;106(10):1697
ATM 2.2 fold Nat Genet. 2015;47(8):906
CHEK2 1.6 fold J Clin Oncol. 2016;34(11):1208
NBN 3.9 fold Cancer Res. 2004;64(4):1215
PALB2 ???
0.4% of metastatic PCa
N Engl J Med. 2016;375(5):443-53
MMR/Lynch 4.9 fold Genet Med. 2014;16(7):553
5. More aggressive PCa (vs. non-carriers)
• BRCA2
• Younger onset, higher T stage, higher Gleason, more LN involvement,
shorter PCa-specific survival and OS1,2
• BRCA2 or BRCA1 or ATM :
• 4-fold higher risk lethal PCa, shorter OS3
• BRCA1 :
• Higher recurrence rates, shorter PCa-specific survival4
1J Natl Cancer Inst. 2007;99(12):929
2J Clin Oncol. 2013;31(14):1748
3Eur Urol. 2017;71(5):740
4Clin Cancer Res. 2010;16(7):2115
Germline DNA repair gene mutations & Prostate Cancer
6. 11.8% (82/692) of men with metastatic
prostate cancer inherited a germline
DNA repair mutation vs 4.6% of
499 men with localized disease
Germline Mutations in Prostate Cancer: 1 in 10
Pritchard CC, et al. N Engl J Med. 2016;375:443-453.
Distribution of Presumed Pathogenic
Germline Mutations
PALB2 4%
RAD51D 4%
ATR 2%
NBN 2%
PMS2 2%
GEN1 2%
MSH2 1%
MSH6 1%
RAD51C 1%
MRE11A 1%
BRIP1 1%
FAM175A 1%
BRCA2 44%
ATM 13%
CHEK2 12%
BRCA1 7%
Gene No. of Mutations % of Men
BRCA2 37 5.35
ATM 11 1.59
CHEK2* 10 1.87
BRCA1 6 0.87
Presumed Pathogenic Germline Mutations
in Metastatic Cases (N = 692)
*n = 534; data censored for metastatic cases with inadequate sequencing.
7. References in slidenotes.
EZH2
AR gene expression
Mutation/gain/V7
PCA3
AMACR
Prostatic
intraepithelial
neoplasia
Localized
PCa
Loss of 8p
(NKX3.1)?
Activation of
β-catenin, wnt
Loss of APC
Castration-
resistant
PCa
Metastatic
PCa
Curable
Incurable
Normal
prostatic
epithelium
Epigenomic changes,
including GSTP1
hypermethylation
Inactivation of p53, RB1, CDK12
ETS gene family
activation via fusion
with TMPRSS2 or other
AR-driven genes
cMYC
Mutations in SPOP, FOXA1, epigenetic regulators
Anaplastic/
NE PCa
Loss of PTEN, 13q (RB1), 5q (CHD1),
16q, 6q, 3p (FOXP1, SHQ1)
Gain of 8q, 3q (PIK3CA)
Tx
Genomic Alterations in Prostate Cancer Progression
Compromised DNA repair
9. DNA Damage Response (DDR)
Cellular DNA is subject to continuous damage from both environmental
agents (mutagens) and endogenous sources
‒ 1000s of events/day (eg, ssDNA and dsDNA breaks, alkylation, x-linked)
DDR has evolved to maintain DNA sequence and fidelity
‒ At least 6 different types of DNA repair processes exist to deal with wide
variety of DNA damage
Inherited defects in DDR are among the most carcinogenic of all
hereditary syndromes (eg, Lynch syndrome, HBOC)
Some DDR defects can be exploited for therapeutic benefit
O’Connor MJ. Mol Cell. 2015;60:547-560.
10. DNA repair gene mutations
• Evolution of next-generation sequencing has allowed germline DNA repair gene mutations
to be linked to PCa
Single strand DNA repair
pathways
Double strand DNA repair pathways
Mismatch repair (MMR) Homologous recombination (HR)
Base excision repair Non-homologous end joining (NHEJ)
Nucleotide excision repair
DNA damage response (DDR)
11. Consequences of DNA Damage
If DNA damage correctly repaired, no consequences
If no repair or inefficient repair due to defects in DDR genes
‒ Cell death is most common fate – unrepaired dsDNA breaks are lethal
‒ Can result in accumulation of DNA damage in the form of mutations
‒ Activation of oncogenes, inactivation of tumor suppressor genes
Accumulation of DNA damage/mutations can lead to cancer
formation/progression
‒ Resulting cancer cells may be more susceptible to drugs that inactivate
remaining DNA repair pathways
Mateo J, et al. Euro Urol. 2017;71:417-425.
13. DNA Repair Defects in Localized Prostate
Cancer
Sequence analysis of localized, nonindolent prostate tumors with
similar risk profiles (N = 477)
– 200 whole-genome sequences, 277 whole-exome sequences
47/477 (9.9%) tumors had DNA repair mutations
– FANCA (n = 9)
– ATM (n = 8)
– RAD51 (n = 7)
– CDK12 (n = 6)
– BRCA2 (n = 5)
Fraser M, et al. Nature. 2017;541:359-364.
14. DNA Repair Defects in mCRPC
34/150 (22.7%) mCRPC pts had DNA repair alterations, many of
which were biallelic
– 19/150 (12.7%) with loss of BRCA2
– ~ 90% were biallelic, with 8/150 (5.3%) resulting from a pathogenic
germline BRCA2 mutation + a somatic event
– Recurrent biallelic loss of ATM also observed, including some
arising from pathogenic germline alterations
– Mutation events also observed in BRCA1, CDK12, FANCA,
RAD51B, and RAD51C
Robinson D, et al. Cell. 2015;5:1215-1228.
15. Genomic Landscape of Advanced Prostate Cancer
23% of metastatic
CRPCs harbor DNA
repair alterations
The frequency of
DNA repair
alterations
increases with
disease
progression
Robinson D et al, Cell, 2015
Robinson D, et al. Cell. 2015;161:1215-1228.
16. DNA Repair Defects in mCRPC: Enrichment Analysis in
Primary vs Metastatic Tumors
Tumor Samples (N = 918)
Primary
Metastasis
583
335
CARD11
Primary
DNA repair defects: 11%
Metastases
DNA repair defects: 21%
Significance
(Fisher’s qvalue)
Genomic Alteration Frequency
AlteredPrimarySamples(%)
Altered Metastatic Samples (%)
50
10
5
30
0
0 5 10 30 50
Amplification/mutation
Homdel/mutation
Mutation
SPOP
PTEN
KMT2C
KMT2D
MYC
FOXA1
TP53
RB1
BRCA2
AR
ZFHX3
CDK12 APC
IDH1
RYBP/FOXP1
JAK1
SPEN
IGF2R
PREX2
CTNNB1
CCND1
FAT1
MGA
MED12
USP28
ANKRD11
GNAS
ERF
CHD8
GRIN2A
RNF43
USP7 ASXL1
SAMD9
Armenia J, et al. ASCO 2017. Abstract 131.
18. PARP Biology
PARP (polyADPribose polymerase) enzymes play a key role in the repair of
ssDNA breaks via BER pathway
Bind directly to sites of DNA damage
Once activated, uses NAD as a substrate to add large, branched chains of
poly(ADP-ribose) polymers (ie, PARylation) to itself and interaction partners
Recruits other DNA repair enzymes to site of damage
DNA damage
NAD+ Nicotinamide
+ pADPr
Lig3XRCC1
Polß
PNK
PARP
Ohmoto A, et al. Onco Targets Ther. 2017;10:5195-5208.
19. PARPi Leads to Increase in dsDNA Breaks
Inhibition of PARP
‒ Prevents recruitment of
DNA repair enzymes to
ssDNA breaks or traps
PARP on DNA
‒ Leads to failure of ssDNA
repair and accumulation
of ssDNA breaks
‒ Replication fork is arrested
at damage, produces dsDNA
breaks
Ohmoto A, et al. Onco Targets Ther. 2017;10:5195-5208.
PARP
XRCC1
DNA
Lig III
PNK 1
DNA
Polβ
During S-phase, replication fork is
arrested at site of ssDNA breaks
Degeneration into
dsDNA breaks
ssDNA
breaks
PARP inhibition
20. Synthetic Lethality Hypothesis
Farmer H, et al. Nature. 2005;434:917-921. Bryant et al. Nature. 2005;434:913-917.
Repair,
Survival
Repair,
Survival
Normal cell
Non-BRCA mutation carrier
PARP function
BRCA function
PARP inhibitor
PARP function
BRCA function
DNA damage
Repair,
Survival
Repair,
Survival
Normal cell
BRCA mutation carrier
(1 allele lost)
PARP function
BRCA function
PARP inhibitor
PARP function
BRCA function
DNA damage
Repair,
Survival
Cell Death
Cancer cell
BRCA mutation carrier
(both alleles lost)
PARP function
BRCA function
PARP inhibitor
DNA damage
PARP function
BRCA function
21. TOPARP: Trial of Olaparib in mCRPC
30 patients 20 patientsTotal: 50 patients
(49 evaluable)
Eligibility: Histologically confirmed metastatic CRPC, ECOG 0-2, no previous PARPi or platinum
Mateo J, et al. N Engl J Med. 2015;373:1697-1708.
FIRST PART:
TREATED
UNSELECTED
mCRPC pts
Randomized study
in unselected
mCRPC pts
Biomarker guided
patient selection in
next part (Part B)
END OF TRIAL
High response rate:
≥ 50% Responding
Intermediate RR
(10-50% responding)
Putative biomarker
identified (RR > 50%)
Low antitumor
activity RR < 10%
23. Radiologic PFS by Presence of Genomic
Defects in DNA Repair Genes
OS by Presence of Genomic Defects in
DNA Repair Genes
ProportionofPatients
ProportionofPatients
Mateo J, et al. N Engl J Med. 2015;373:1697-1708.
0
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 101112 131415 16171819 20
Mos Since Trial Entry
Log-rank P < .001
Biomarker positive,
median: 9.8 mos
Biomarker negative,
median: 2.7 mos
0
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 101112 131415 16171819 20
Mos Since Trial Entry
Log-rank P = .05
Biomarker positive,
median: 13.8 mos
Biomarker negative,
median: 7.5 mos
TOPARP-A: PFS and OS by Presence of DNA Repair
Defects
All patients (N = 50) treated with olaparib 400 mg PO BID
24. De Felice F, et al. Drug Des Devel Ther. 2017;11:547-552.
Olaparib: Ongoing Studies in Prostate Cancer
Trial Study Design Eligibility Study Arms Endpoint Results
TOPARP Phase II Advanced CRPC Oral olaparib ORR 33% ORR
Kaufman, et al Phase II
BRCA1/2-mut adv solid
tumors (PC n = 8)
Oral olaparib ORR
PFS: 9.8 vs 2.7 mos
OS: 13.8 vs 7.5 mos
ORR in PC: 50%
NCT01972217
Randomized
phase II
mCRPC Olaparib + abiraterone Safety
PFS: 7.2 mo
OS: 18.4 mo
(ongoing study)
NCT02484404 Phase I/II
Adv/recurrent solid
tumors
Anti-PD-L1 + olaparib Safety
Recommended
dose (ongoing)
KEYNOTE 365 Phase I/II mCRPC
Anti-PD-L1 + cediranib
± olaparib
Pembro + olaparib
Safety
AEs, ORR, OS
(ongoing)
NCT02893917
Randomized
Phase II
mCRPC Olaparib + cediranib PFS
PFS, RR, OS
(ongoing)
NCT02324998 Phase I Int/high-risk PC Olaparib ± placebo
Degree of
PARPi
AEs (ongoing)
27. PD-1 Inhibition in MMR-Deficient Cancers
Le DT, et al. ASCO 2016. Abstract 103. Le DT, et al. N Engl J Med. 2015;372:2509-2520.
Radiographic Response With Pembrolizumab
-100
MMR-P CRC
MMR-D CRC
MMR-D non-CRC
ChangeFromBLinthe
SumofLongest
Diameters(%)
20% increase (PD)
100
0
50
-50 30% decrease (PR)
Biochemical Response With Pembrolizumab
MMR-P CRC
MMR-D CRC
MMR-D non-CRC
ChangeinTumor
MarkerLevel(%)
Days
0% (no change)
200
0
-100
0 100 200 400300
100
Pt
PFS(%)
PFS with Pembrolizumab
Mos
MMR-D
(mPFS: NR)
100
50
0
0 3 6 12 15 18 21 24 27 30
MMR-P
(mPFS: 2.3 mos)
9
OS(%)
Mos
MMR-D
(mOS: NR)
OS with Pembrolizumab100
50
0
0 3 6 12 15 18 21 24 27 30
MMR-P
(mOS: 5.98 mos)
9
28. Pembrolizumab for MSI-H or MMR-Deficient
Cancers
In May 2017, the PD-1 inhibitor pembrolizumab received
accelerated approval from FDA for:
– MSI-H or MMR-deficient CRC that has progressed following
treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
– For ALL unresectable or metastatic MSI-H or MMR-deficient
SOLID TUMORS (pediatric and adult) that have progressed on
prior treatment and with no satisfactory alternative treatment
options
Dosage and administration (MSI-H cancers): 200 mg IV every 3
wks
Pembrolizumab [package insert]. 2017.
29. KEYNOTE-016: Responses to Pembrolizumab in
MMR-Deficient Tumors
Radiographic responses across 12 tumor types at 20 wks (N = 86)
Le DT, et al. Science. 2017;357:409-413.
Ampulla of Vater
Cholangiocarcinoma
Colorectal
Endometrial cancer
Gastroesophageal
Neuroendocrine
Osteosarcoma
Pancreas
Prostate
Small Intestine
Thyroid
Unknown primary
100
50
0
-50
-100
ChangeFrom
BaselineSLD(%)
Prostate
Prostate
(n = 1)
31. Conclusions
DNA repair mutations are common in prostate cancer, particularly mCRPC
‒ Both somatic and germline mutations can lead to DNA repair defects
20% to 30% of metastatic CRPCs harbor alterations in DNA repair genes
HR DNA repair mutations sensitize to PARP inhibitors
‒ “Synthetic lethality” hypothesis in action
MMR mutations are rare...but may sensitize to immune checkpoint
inhibitors